Your browser doesn't support javascript.
loading
Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C; Fasching, Peter A; Hein, Alexander; Burghaus, Stefanie; Beckmann, Matthias W; Lambrechts, Diether; Van Nieuwenhuysen, Els; Vergote, Ignace; Vanderstichele, Adriaan; Doherty, Jennifer Anne; Rossing, Mary Anne; Chang-Claude, Jenny; Rudolph, Anja; Wang-Gohrke, Shan; Goodman, Marc T; Bogdanova, Natalia; Dörk, Thilo; Dürst, Matthias; Hillemanns, Peter; Runnebaum, Ingo B; Antonenkova, Natalia; Butzow, Ralf; Leminen, Arto; Nevanlinna, Heli; Pelttari, Liisa M; Edwards, Robert P; Kelley, Joseph L; Modugno, Francesmary; Moysich, Kirsten B; Ness, Roberta B; Cannioto, Rikki; Høgdall, Estrid; Høgdall, Claus; Jensen, Allan; Giles, Graham G; Bruinsma, Fiona; Kjaer, Susanne K; Hildebrandt, Michelle A T; Liang, Dong; Lu, Karen H; Wu, Xifeng; Bisogna, Maria; Dao, Fanny; Levine, Douglas A; Cramer, Daniel W; Terry, Kathryn L; Tworoger, Shelley S; Stampfer, Meir.
Afiliação
  • Cuellar-Partida G; Statistical Genetics, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, 4006, Australia. gabriel.cuellar@qimrberghofer.edu.au.
  • Lu Y; School of Medicine, University of Queensland, St Lucia, QLD, 4072, Australia. gabriel.cuellar@qimrberghofer.edu.au.
  • Dixon SC; Statistical Genetics, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, 4006, Australia.
  • Fasching PA; School of Public Health, University of Queensland, Herston, QLD 4006, Australia.
  • Burghaus S; Division of Hematology and Oncology, Department of Medicine, University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, USA.
  • Beckmann MW; Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
  • Lambrechts D; Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
  • Van Nieuwenhuysen E; Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
  • Vergote I; Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, University Hospital Erlangen, Universitaetsstrasse 21-23, 91054, Erlangen, Germany.
  • Vanderstichele A; Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium.
  • Doherty JA; Vesalius Research Center, VIB, Louvain, Belgium.
  • Rossing MA; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Louvain, Belgium.
  • Chang-Claude J; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Louvain, Belgium.
  • Rudolph A; Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Louvain, Belgium.
  • Wang-Gohrke S; Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH, USA.
  • Goodman MT; Department of Epidemiology, University of Washington, Seattle, WA, USA.
  • Bogdanova N; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Dörk T; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Dürst M; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hillemanns P; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Runnebaum IB; Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany.
  • Antonenkova N; Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Butzow R; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Community and Population Health Research Institute, Los Angeles, CA, USA.
  • Leminen A; Radiation Oncology Research Unit, Hannover Medical School, Hannover, Germany.
  • Nevanlinna H; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Pelttari LM; Department of Gynecology, Jena-University Hospital-Friedrich Schiller University, Jena, Germany.
  • Edwards RP; Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany.
  • Kelley JL; Department of Gynecology, Jena-University Hospital-Friedrich Schiller University, Jena, Germany.
  • Modugno F; N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus.
  • Moysich KB; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Ness RB; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Cannioto R; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Høgdall E; Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Høgdall C; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Jensen A; Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Giles GG; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Bruinsma F; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Kjaer SK; Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Hildebrandt MA; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.
  • Liang D; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Lu KH; The University of Texas School of Public Health, Houston, TX, USA.
  • Wu X; Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Bisogna M; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Dao F; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Levine DA; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Cramer DW; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Terry KL; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
  • Tworoger SS; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
  • Stampfer M; Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia.
Hum Genet ; 135(7): 741-56, 2016 07.
Article em En | MEDLINE | ID: mdl-27075448
ABSTRACT
Epithelial ovarian cancer (EOC) is one of the deadliest common cancers. The five most common types of disease are high-grade and low-grade serous, endometrioid, mucinous and clear cell carcinoma. Each of these subtypes present distinct molecular pathogeneses and sensitivities to treatments. Recent studies show that certain genetic variants confer susceptibility to all subtypes while other variants are subtype-specific. Here, we perform an extensive analysis of the genetic architecture of EOC subtypes. To this end, we used data of 10,014 invasive EOC patients and 21,233 controls from the Ovarian Cancer Association Consortium genotyped in the iCOGS array (211,155 SNPs). We estimate the array heritability (attributable to variants tagged on arrays) of each subtype and their genetic correlations. We also look for genetic overlaps with factors such as obesity, smoking behaviors, diabetes, age at menarche and height. We estimated the array heritabilities of high-grade serous disease ([Formula see text] = 8.8 ± 1.1 %), endometrioid ([Formula see text] = 3.2 ± 1.6 %), clear cell ([Formula see text] = 6.7 ± 3.3 %) and all EOC ([Formula see text] = 5.6 ± 0.6 %). Known associated loci contributed approximately 40 % of the total array heritability for each subtype. The contribution of each chromosome to the total heritability was not proportional to chromosome size. Through bivariate and cross-trait LD score regression, we found evidence of shared genetic backgrounds between the three high-grade subtypes serous, endometrioid and undifferentiated. Finally, we found significant genetic correlations of all EOC with diabetes and obesity using a polygenic prediction approach.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Epiteliais e Glandulares / Patologia Molecular / Genótipo Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Epiteliais e Glandulares / Patologia Molecular / Genótipo Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article